SCHEMBL5474271

SCHEMBL5474271

CS(=O)(=O)Nc1ccc(C2(c3ccc(NS(C)(=O)=O)cc3)C(=O)Nc3sc(Cl)cc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.40
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNA2 P20248 1/20 0.36
CCND1 P24385 1/20 0.36
CDK2 P24941 1/20 0.36
CDK7 P50613 1/20 0.36
CCNH P51946 1/20 0.36
CCNA1 P78396 1/20 0.36
CDK6 Q00534 1/20 0.36
TDP2 O95551 1/20 0.36
MET P08581 2/20 0.36
PGR P06401 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
KEAP1 Q14145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482310 0.77 SMN1; SMN2 (0.38) KIF11TDP2PGRSMN1; SMN2ALDH1A1
SCHEMBL5482571 0.74 KIF11 (0.40) KIF11TDP2METPGRSMN1; SMN2
SCHEMBL5484218 0.73 KIF11 (0.42) KIF11TDP2METPGRSMN1; SMN2
SCHEMBL5485549 0.72 KIF11 (0.40) KIF11TDP2PGRSMN1; SMN2ALDH1A1
SCHEMBL5479295 0.71 KIF11 (0.40) KIF11PGRHPGDKDM4ELMNA
SCHEMBL5478650 0.69 KIF11 (0.38) KIF11TDP2PGRSMN1; SMN2ALDH1A1
SCHEMBL5480164 0.67 KIF11 (0.38) KIF11TDP2METPGRSMN1; SMN2
SCHEMBL5478102 0.67 KEAP1 (0.38) KIF11TDP2METPGRSMN1; SMN2
SCHEMBL5483547 0.67 SMN1; SMN2 (0.37) KIF11TDP2METPGRSMN1; SMN2
SCHEMBL5480073 0.66 MET (0.44) METPGRSMN1; SMN2HTTKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 KIF11 4188/4885CDK1 37/4885CCNB1 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.